Alcohol Use Disorder: Causes, Symptoms, Treatment & Prevention
Screening tools, withdrawal syndromes, medication-assisted treatment hooks, organ complications, and escalation—written for nurses and allied clinicians in hospital and community pathways.
Featured snippet
Alcohol use disorder (AUD) is a chronic, relapsing condition marked by impaired control over drinking, compulsive use, craving, tolerance, withdrawal on reduction, and continued use despite harm. Nurses anchor safety during unplanned cessation (withdrawal monitoring, thiamine protocols, escalation when autonomic storming or delirium appears) and coordinate biopsychosocial care alongside prescribers trained in addiction medicine.
Clinical snapshot: Treat heavy daily intake as a potential medical emergency until triaged—time since last drink, prior complicated withdrawal, polysubstance use, and cirrhosis clues change sedation and monitoring intensity, not just “detox comfort.”
- Withdrawal risk stratification starts at triage: last drink timing, prior seizure history or ICU detox, concurrent sedative or opioid exposure, pregnancy, and major comorbidity drive observation level and medication pathway.
- CIWA-Ar (or local equivalent) records symptoms—not a stand-alone brain; pair scores with vital signs, hydration, glucose checks, and nursing gestalt when patients cannot self-report reliably.
- Before glucose loads in malnourished drinkers, administer parenteral/oral thiamine per protocol to mitigate Wernicke encephalopathy risk; repeat dosing follows hepatology/addiction service guidance.
- FDA-listed medications for maintenance include naltrexone, acamprosate, and disulfiram—each carries distinct adherence, safety, and interaction checks nurses reinforce at teaching and reconciliation.
- Longitudinal harm tracks through liver biochemistry, nutrition, mood disorder relapses, bleeding risk, and social instability—flag cirrhosis red flags for urgent hepatology input.
⚡ Quick Facts
*Individual timelines vary with pattern, genetics, and co-ingestants—never discharge on timing alone without clinical clearance.
💡 Clinical Pearl
The “talkative detox” trap: Patients who look comfortable conversationally may still harbor climbing autonomic instability or subtle hallucinations. Pair bedside CAM or CAM-ICU style attention testing with objective trends—especially in hypoalbuminemia or concurrent infections where benzodiazepine metabolism wobbles.
📋 Contents
What is Alcohol Use Disorder?
Alcohol use disorder is a medical condition in which a person loses reliable control over drinking despite harmful consequences in health, relationships, or role functioning. Contemporary diagnostic frameworks anchor it to a pattern of cognitive, behavioural, and physiological symptoms arising from neuroadaptation in reward, stress, and executive-control circuits after repeated heavy ethanol exposure.
From a nursing vantage, AUD rarely presents as a single “addiction ward” diagnosis—it surfaces through trauma bay intoxication, decompensated cirrhosis, pancreatic inflammation, withdrawal on medical wards, infections, falls, and undertreated mood disorders. Framing it as a chronic illness reduces stigma and aligns monitoring with guideline expectations for screening, withdrawal safety, organ screening, and relapse-prevention counselling handoffs.
Resource-constrained services still expect clinicians to detect hazardous use early, stabilize acute medical complications, and connect patients with structured psychosocial care or pharmacotherapy—documentation of drinking quantity, timing of last drink, and prior detox outcomes materially changes risk triage the first night of admission.
Severity & diagnostic criteria
DSM-5-TR defines AUD through 11 criteria experienced within a year; meeting 2–3 defines mild, 4–5 moderate, and 6 or more severe. Severity guides psychosocial intensity, consideration of medication-assisted treatment, and safeguarding discussions—yet nurses should remember that acute instability (bleeding risk, encephalopathy, suicidality) can outrank a mild label on paper.
| Domain | Examples clinicians elicit | Nursing observation tie-ins |
|---|---|---|
| Loss of control | Larger amounts/longer episodes than intended; failed cut-down attempts | Inventory hidden bottles, request collateral from partners; look for hand tremor when history vague |
| Craving / time spent | Strong urges; afternoons lost to drinking or recovery | Ask about morning anxiety and protective drinking patterns |
| Risk / tolerance / withdrawal | Hazardous use; escalating doses; nausea, sweats, seizures when abstinent | Correlate CIWA items with electrolyte and magnesium trends; watch for hallucinations and fluctuating attention |
| Role harm & persistence | Continued drinking despite organ injury, job loss, or conflict | Link abnormal LFTs or GI bleeds to motivational interviewing referrals once stable |
On a small screen, swipe or scroll sideways to see the full table.
Escalate acute services early when withdrawal features suggest delirium tremens or severe autonomic storming:
- Marked confusion with inattention plus fluctuating course after recent reduction in drinking—perform structured delirium screening and compare with baseline cognition.
- Visual or tactile hallucinations, agitation, fever, or profoundly labile blood pressure/pulse despite escalating protocol lorazepam dosing per prescriber order.
- Withdrawal seizures or a first motor seizure in a known heavy drinker—assume secondary work-up per emergency pathway, not “benign detox.”
- Suspected Wernicke encephalopathy (ocular signs, gait ataxia, confusion triad—may be incomplete)—coordinate high-dose thiamine regimens with medical staff even before imaging arrives.
Immediate actions: Ensure continuous monitoring capability, suction and airway adjuncts available, two large-bore IV lines if bleeding risk, correct hypoglycaemia cautiously after thiamine per protocol, and notify the most responsible physician when features exceed monotherapy nursing expectations.
Symptoms
AUD symptoms span intoxication phenomena, neuropsychiatric withdrawal, and cumulative organ injury—often simultaneously. Patients may minimise them; corroborate with partners, employers, prior ED visits, and pharmacy data when safety allows.
Behavioural and cognitive features
- Craving, preoccupation with obtaining alcohol, and unsuccessful attempts to cut down despite commitments.
- Drinking despite knowledge of alcoholic hepatitis, relationship conflict, or workplace warnings.
- Low mood, irritability, panic symptoms, and sleep fragmentation—overlap heavily with major depression and anxiety disorders.
Physical clues on presentation
- Transient hypertension/tachycardia with fine tremor during withdrawal; later hypotension when bleeding or sepsis complicate.
- Stigmata of chronic disease: jaundice, ascites, muscle wasting, palmar erythema—think advanced cirrhosis when exam fits.
- Acute pancreatic inflammation, fractures, or head trauma from intoxication-related injury.
Variant presentations to anticipate
- Older adults with quiet confusion from interplay of withdrawal, infection, and polypharmacy.
- Professionally employed “high-functioning” drinkers who meet criteria but lack social chaos—screening scores still flag risk.
- Patients with alcohol-flush or acetaldehyde syndromes—distinct pathophysiology from AUD but may co-exist with hazardous drinking attempts.
Causes and Risk Factors
AUD emerges when genetic loading, early exposure, neurobiological vulnerability, and environmental availability intersect. Harm begins well before dependence in many pathways; nurses capture modifiable drivers for motivational work once acute safety is secured.
Biological predisposition
Family history and heritable traits influencing impulsivity, stress reactivity, and alcohol metabolism shape trajectory; liability is not destiny—structured treatment still shifts outcomes.
Psychosocial stressors
- Trauma, occupational strain, and housing or food insecurity increase reliance on alcohol as coping.
- Comorbid mental illness—especially mood and anxiety disorders—raises bidirectional risk.
- Peer density of heavy drinking and advertising exposure normalise hazardous quantities.
Medical amplifiers
- Hepatitis C virus (HCV overview) accelerates fibrosis when concomitant heavy drinking persists—offer testing when risk factors cluster.
- Pain syndromes managed with sedatives or opioids complicate withdrawal and MAT sequencing—always reconcile controlled drugs.
How is it Diagnosed?
Diagnosis blends a structured history for DSM-5 criteria, validated questionnaires, collateral when consented, physical exam, and targeted labs/imaging for complications. No single biomarker defines AUD; heavy drinking also harms organs before formal dependence appears.
Clinical assessment
Quantify standard drinks, drinking days per week, heaviest recent binge, longest sober period, prior complicated withdrawal, suicidality, and readiness to change. Use admission assessment templates to lock collateral contacts and safeguarding risks.
Laboratory investigations
- Baseline liver profile, glucose, renal panel, CBC, coagulation when cirrhosis suspected; trend magnesium/electrolytes during diuresis or vomiting.
- Ammonia when hepatic encephalopathy features coexist with withdrawal agitation—helps separate diagnoses.
- Viral hepatitis serologies where risk or transaminitis warrants—not every admission, but high-yield in multi-morbid drinkers.
Structured screening & scoring
AUDIT-C or full AUDIT, plus CAGE where brevity required, identify hazardous use in primary care and hospital triage; abnormal scores trigger fuller assessment—not automatic labels without clinical correlation.
Withdrawal severity tools
CIWA-Ar (or CIWA-AD where validated) standardises tremor, diaphoresis, anxiety, agitation, sensory disturbances, headache, and orientation for protocolised benzodiazepine titration—pair with serial vitals and telemetry when indicated.
Monitoring cadence after initial stabilisation
| Setting / trigger | Typical nursing focus |
|---|---|
| Inpatient detox night 0–3 | Hourly-to-q2h scoring until trending down; watch occult GI bleed and infection mimics. |
| Outpatient start of oral naltrexone | Confirm opioid-negative status; review nausea and injection-site issues; safety counselling on overdose risk if relapse + opioids. |
| Cirrhosis + abstinence push | Six-week LFT trend where requested, ascites girth, encephalopathy precautions, dietitian protein review. |
On a small screen, swipe or scroll sideways to see the full table.
Clinical decision flow
Simplified ward triage; all medication orders remain prescriber-led and pathway-specific.
- Unstable vitals + recent cessation + hallmark withdrawal: activate detox observation, secure IV access if needed, give thiamine per protocol, obtain baseline labs, avoid sedating co-interventions that mask scores without order.
- Possible mixed opioid/sedative withdrawal: involve toxicology/pharmacy early; monitored naloxone assessment remains a senior-directed manoeuvre in equipped units.
- Escalating CIWA despite protocol benzodiazepines: senior review for ICU thresholds, alternative aetiologies (sepsis, intracranial event), and refractory pathway options.
- Altered mental status jaundiced patient: broaden beyond withdrawal—consider infection, GI bleed, hyponatraemia, and encephalopathy.
- Discharge planning: addiction service, primary care MAT, peer support, and safeguarding referrals documented before leave.
Differential Diagnoses
Withdrawal patterns overlap with other emergencies; bias toward concurrent disease rather than a single tidy label.
| Mimic / comorbidity | Clues & tests |
|---|---|
| Sedative-hypnotic withdrawal | Similar autonomic surge; history of benzodiazepine-class agents; often longer duration; collateral pharmacy essential. |
| Acute intoxication / toxicity | Prominent CNS depression, hypoglycaemia, aspiration—does not improve solely with symptom-triggered benzos without airway protection plan. |
| Hepatic encephalopathy | Asterixis, constructed bias on psychometric tests, ammonia often elevated—avoid attributing all agitation to withdrawal. |
| Head injury / subdural | Focal neuro signs after falls; maintain low threshold for imaging when mechanism unclear or intoxication severe. |
| Wernicke encephalopathy | Ocular palsy, ataxia, confusion triad may be partial—treat empirically with IV/IM high-dose thiamine regimens when suspicion medium-high. |
On a small screen, swipe or scroll sideways to see the full table.
Treatment Options
AUD management stacks psychosocial interventions, relapse-prevention pharmacotherapy where appropriate, and parallel treatment of organ disease. Nurses execute monitoring curves, reconcile risky drug combinations, and surface barriers to access.
Psychosocial first-line
- Motivational interviewing, cognitive-behavioural therapy, contingent management, and 12-step facilitation show benefit depending on context—document which modality the patient can realistically attend.
- Digital and telehealth supports expand reach; still verify identity, privacy, and crisis contingencies.
Medically managed withdrawal (inpatient or structured outpatient)
- Long-acting benzodiazepines such as diazepam or symptom-triggered lorazepam regimens remain cornerstone—titrate only within standing orders and track respiratory status especially with adjunct sedatives.
- Ondansetron addresses refractory nausea; watch QT prolongation when protocols mandate ECG surveillance.
- Alpha-2 agonists or anticonvulsants (for example gabapentin, topiramate) appear in selected pathways—never substitute ad hoc for benzodiazepines in established complicated withdrawal without senior direction.
Relapse-prevention / maintenance medications
- Naltrexone (oral or extended-release injectable) reduces reward signalling—verify opioid abstinence and counsel on hepatotoxicity vigilance.
- Acamprosate modulates glutamate hyperactivity post-abstinence; emphasise GI tolerance and renal dosing rules from pharmacy.
- Disulfiram enforces aversive acetaldehyde buildup—absolute alcohol avoidance and cardiovascular review before start.
- Off-label options such as bupropion or sertraline target comorbid depression while supporting abstinence endpoints in specialist hands.
Augmentation cautions
Use antipsychotics such as haloperidol for severe agitation only with explicit medical orders—QT and seizure risk coexist with heavy alcohol withdrawal.
Special populations
- Cirrhosis / porto-systemic shunting: dose-adjust benzos, involve hepatology for ammonia and encephalopathy plans.
- Pregnancy: multidisciplinary obstetric–addiction care—never assume safety of abrupt unsupervised cessation.
- Adolescents: developmental and safeguarding laws vary; family involvement needs consent frameworks.
Clinical Practice Considerations
Operational expectations for nurses coordinating multi-day detox, medical floors, or ambulatory MAT clinics.
| Domain | Cadence / action |
|---|---|
| Withdrawal scoring | Record score, time, intervention, response; flag “unable to assess” when cognition falters. |
| Fluid & nutrition | Oral diet as tolerated; IV fluids per order; track glucose in malnourished patients. |
| Laboratory follow-up | Repeat abnormal LFTs per protocol (often 6–12 weeks after abstinence push); add INR and albumin when cirrhosis suspected. |
| Psychiatric safety | Serial suicide screens during sobering—impulse control often worse before better. |
| Handover | State last drink time, CIWA trajectory, benzo milligrams given, and pending psych consults—avoid vague “detoxing” labels. |
On a small screen, swipe or scroll sideways to see the full table.
Treatment failure in AUD usually means lost follow-up, undertreated craving, or unaddressed housing—not “non-compliance.” Flag social determinants early.
Possible Complications
Direct toxicity, secondary malnutrition, and trauma interact—complications often arrive in bundles.
Acute and subacute
- Withdrawal seizures, delirium tremens, aspiration, and arrhythmias during sympathetic surges.
- Pancreatitis, massive GI bleed from varices, and alcoholic hepatitis flares.
- Hypoglycaemia, rhabdomyolysis, and electrolyte catastrophes after binge termination.
Chronic
- Cirrhosis with portal hypertension, HCC surveillance needs, and infection susceptibility.
- Neurocognitive decline plus cerebellar degeneration from thiamine deficiency states.
- Sustained mood or anxiety disability even after biological withdrawal resolves.
Prevention
Primary prevention centres on population-level pricing, licensed sales enforcement, and brief interventions when screening flags hazardous use—clinicians should know local SBIRT or audit programmes.
Clinician-facing prevention tasks
- Routinely screen adults per USPSTF-grade evidence and offer brief counselling or referral—document standard-drink education.
- Vaccinate cirrhosis cohorts against pneumococcus and hepatitis B where indications exist alongside HCV treatment offers.
- Negotiate realistic drinking targets when absent total abstinence—some systems prioritise harm reduction bridging to abstinence.
Prognosis and Outlook
Many people achieve durable remission with combined pharmacologic and psychosocial care; relapse remains common and should trigger reassessment—not punishment. Earlier treatment engagement and fewer withdrawal complications predict better function at 12 months in cohort studies.
- Mortality concentrates in liver failure, trauma, malignancy, and cardiomyopathy when drinking persists—honest organ-stage conversations matter.
- Recovery capital (housing, employment, supportive peers) often dictates staying power more than initial motivation scores.
In Clinical Practice…
Ward habits that reduce error and stigma:
- Replace judgemental chart labels with objective behaviour descriptors (“CIWA 18, tremor ++, oriented ×3”).
- Offer trauma-informed language options—some patients refuse “alcoholic” but accept “AUD” or “dependence.”
- Secure phones/chargers when safeguarding against dealers or betting triggers, per institutional policy.
- Double-check anaesthesia and sedation plans with anaesthetics when recent heavy use is suspected even if currently sober.
Bedside monitoring checklist (AUD / withdrawal)
Repeat until clinically stable or stepped down:
- Airway & breathing: snoring pattern, SpO2, need for aspiration precautions after emesis.
- Neuro: CAM q-shift when delirium risk; pupil symmetry; seizure pads and timing device at bedside.
- CV: MAP goals per bleeding risk; orthostatic vitals when diuresing.
- GI / metabolic: glucose checks, LFT trend awareness, stool colour for covert bleed.
- Meds: thiamine doses given, benzodiazepine cumulative totals, allergy bands for disulfiram if applicable.
When to Seek Emergency Care
Activate emergency services or critical-care outreach when withdrawal or organ complications breach ward comfort thresholds.
- Respiratory depression, SpO2 fall, or inability to protect airway during sedation titration.
- Persistent delirium with violent agitation, core temperature >38.3 °C, or MAP variability despite protocol therapy.
- Witnessed tonic-clonic seizure, repeated seizures without full recovery, or focal deficit new after trauma.
- Hematemesis, melaena, or rapid haemoglobin drop—variceal haemorrhage kills faster than withdrawal alone.
- Suicidal ideation with plan/intent, homicide risk, or inability to contract for safety.
Until responders arrive: lateral recovery position if unconscious, oxygen if hypoxic, glucose check, stay with patient, time seizure length, and hand over last benzodiazepine milligrams administered.
Clinical signs of deterioration and when to escalate
Treat any sudden departure from expected detox trajectory as a trigger to broaden the differential—not merely “a bad night.”
Red-flag symptom patterns
- CIWA scores trending up despite repeated PRN doses or emergence of new hallucinations.
- Persistent vomiting preventing oral thiamine or medication absorption—risk Wernicke progression.
- Escalating abdominal pain or guarding suggesting pancreatitis or perforation.
- Jaundice deepening over 24–48 h or encephalopathy waxing—think acute-on-chronic liver failure.
Objective cues
- Widening pulse pressure swings, new atrial arrhythmias, or silent ischaemia on telemetry.
- Rapid INR rise, falling platelets, or lactate elevation without clear infection source.
- Hyponatraemia overly corrected—watch for osmotic demyelination in chronic drinkers.
Escalation mechanics
- Ward: senior review plus ICU liaison when benzodiazepine requirements exceed pathway comfort or airway concern appears.
- Community: instruct patients/partners to call emergency services for seizure, uncontrolled vomiting, hematemesis, or suicidal urge with access to means.
Nursing management
Nursing spans humane withdrawal monitoring, teaching, safeguarding, and warm handoffs to longer-term recovery systems.
Admission & first 24 h
- Complete alcohol, sedative, opioid timeline; involve pharmacy for high-risk reconciliation.
- Start thiamine and offer balanced meals when safe—anticipate hypophosphataemia refeeding risk in severe malnutrition per protocol.
Active detox shifts
- Maintain low-stimulus environment; cluster vitals to preserve sleep where policy allows.
- Coach patients through craving peaks using de-escalation language; involve peers when available.
MAT & education
- Teach hidden alcohol sources for disulfiram patients and emphasise carry emergency contact cards.
- Reinforce that depressive symptoms may transiently worsen after cessation—pre-plan crisis numbers.
Discharge safety-netting
- Book hepatology or addiction clinic prior to leave when LFTs abnormal or alcoholic hepatitis suspected.
- Confirm naloxone supply and training when opioid risk coexists with relapse potential.
NCLEX practice questions
These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and cloze drops on the topic of alcohol use disorder (DSM-5 criteria), CIWA-Ar guided withdrawal management, IV thiamine for Wernicke prophylaxis and the AUDIT-C / pharmacotherapy ladder.
Unfolding case (Questions 1–3): Mr. B., 54, presents to the ED 16 hours after his last drink with tremor, anxiety, sweating, mild hypertension (BP 156/96, HR 110) and nausea. He has been drinking 25–30 units / day for 8 years. CIWA-Ar 14, glucose 4.6, mild ataxia, no confusion. Past medical history: untreated hypertension, fatty liver on imaging. He has previously had a withdrawal seizure.
Answer key & rationale
When should thiamine precede glucose in the AUD admission work-up?
Give parenteral/oral thiamine per protocol before carbohydrate loads when Wernicke risk is plausible—malnutrition, recurrent vomiting, suspected decompensated liver disease, or altered cognition—to reduce precipitating acute encephalopathy.
How often are CIWA-Ar or equivalent scales monitored during inpatient detox?
Typically every 1–4 hours until stable, then spacing per local pathway as scores plateau; escalate frequency when scores rise or hallucinations appear—never treat the number without the whole clinical picture.
Which AUD pharmacotherapy requires opioid abstinence screening first?
Mu-opioid antagonists such as naltrexone can precipitate withdrawal in opioid-dependent patients—coordinate urine drug testing, overdose history, and specialist bridging plans before initiation.
What labs best track evolving alcohol-related organ injury during early sobriety?
Trend liver biochemistry (including AST/ALT context), coagulation when cirrhosis suspected, electrolytes/magnesium, and ammonia when encephalopathy features appear—pair with clinical exam for jaundice, ascites, and asterixis.
What distinguishes uncomplicated withdrawal from delirium tremens on the floor?
Delirium tremens combines altered attention with autonomic instability and often perceptual disturbances 48–96 h after last drink (timing variable). It is a medical emergency—notify the acute team and prepare escalation/ICU discussion.
How should nurses document alcohol types and timing?
Capture standard-drink equivalents, daily pattern versus binges, time of last drink, prior withdrawal seizures or ICU detox, and concurrent sedative or opioid use—precision changes benzodiazepine risk stratification.
Can disulfiram be started during active morning drinking?
No—ensure confirmed abstinence baseline and eliminate alcohol-containing products; counsel about aversive reaction risk and screen for cardiac/cerebrovascular contraindications per prescriber protocol.
What follow-up interval is reasonable after outpatient MAT initiation?
Many programmes review adherence, craving, and adverse effects within 1–2 weeks of start or dose change, then monthly if stable—sooner if suicidality, severe insomnia, or bleeding risk signs emerge.
When is referral to addiction psychiatry or hepatology urgent?
Refer urgently for decompensated liver disease, refractory withdrawal despite protocol benzodiazepines, polysubstance withdrawal, pregnancy with heavy dependence, or suicidal ideation with concrete plan—local hub services vary.
Why ask about acetaminophen and NSAID overuse in AUD patients?
Occult analgesic exposure atop alcoholic liver disease raises hepatotoxicity and bleeding risk—reconciliation informs safer analgesic plans during detox and comorbid pain care.
- National Institute for Health and Care Excellence (NICE). Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence (CG115).nice.org.uk/guidance/cg115
- National Institute for Health and Care Excellence (NICE). Alcohol-use disorders: diagnosis and management of physical complications (CG100).nice.org.uk/guidance/cg100
- National Institute for Health and Care Excellence (NICE). Alcohol-use disorders: diagnosis and management (QS11).nice.org.uk/guidance/qs11
- U.S. Preventive Services Task Force. Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (final recommendation).uspreventiveservicestaskforce.org (USPSTF statement)
- National Institute on Alcohol Abuse and Alcoholism (NIAAA). Understanding Alcohol Use Disorder (fact sheet, updated January 2025).niaaa.nih.gov (AUD fact sheet)
- Centers for Disease Control and Prevention. Alcohol use and your health.cdc.gov/alcohol/about-alcohol-use
- World Health Organization. Alcohol fact sheet.who.int (alcohol fact sheet)
- NHS UK. Alcohol-use disorder.nhs.uk/conditions/alcohol-misuse
- National Center for Biotechnology Information Bookshelf. StatPearls. Alcohol Use Disorder.ncbi.nlm.nih.gov/books/NBK436003
- Choudhary M, Malik M, Dhaliwal U, et al. Alcohol Withdrawal Syndrome: Benzodiazepines and Beyond. J Clin Diagn Res. 2015.ncbi.nlm.nih.gov/pmc/articles/PMC4606320
- U.S. Department of Health and Human Services. Alcohol and Cancer Risk (Surgeon General priorities).hhs.gov/surgeongeneral/priorities/alcohol-cancer
- National Institute on Drug Abuse (NIDA). Alcohol research topic overview.nida.nih.gov/research-topics/alcohol